Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

BACKGROUND: The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in few durable remissions. Bruton's tyrosine kinase (BTK), an essential component of B-cell–receptor signaling, mediates interactions with the tumor microenvironment and promotes the survival and proliferation...

Full description

Saved in:
Bibliographic Details
Main Authors: Byrd, John C., Furman, Richard R., Coutre, Steven E., Flinn, Ian W., Burger, Jan A., Blum, Kristie A., Grant, Barbara, Sharman, Jeff P., Coleman, Morton, Wierda, William G., Jones, Jeffrey A., Zhao, Weiqiang, Heerema, Nyla A., Johnson, Amy J., Sukbuntherng, Juthamas, Chang, Betty Y., Clow, Fong, Hedrick, Eric, Buggy, Joseph J., James, Danelle F., O'Brien, Susan
Format: Artigo
Language:Inglês
Published: 2013
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3772525/
https://ncbi.nlm.nih.gov/pubmed/23782158
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1215637
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items